FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Welcome to OncLive On Air^®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Shannon N. Westin, MD, MPH, FACOG, about the FDA approval of durvalumab (Imfinzi) plus chemotherapy for patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer. Dr Westin is a professor and the clinical medical director of the Department of Gynecologic Oncology and Reproductive Medicine in the Division of Surgery at The University of Texas MD Anderson Cancer Center in Houston.

On June 14, 2024, the FDA approved the combination of durvalumab, carboplatin, and paclitaxel, followed by single-agent durvalumab, for the treatment of adult patients with primary advanced or recurrent dMMR endometrial cancer. This regulatory decision was supported by findings from the phase 3 DUO-E trial (NCT04269200), in which patients with dMMR tumors who received the durvalumab regimen (n = 46) achieved a median progression-free survival that was not reached (NR; 95% CI, NR-NR) vs 7 months (95% CI, 6.7-14.8) for patients who received placebo plus chemotherapy (n = 49; HR, 0.42; 95% CI, 0.22-0.80).

In our exclusive interview, Dr Westin discussed the significance of this approval, key efficacy and safety data from DUO-E, and what the future looks like for this combination in the endometrial cancer treatment paradigm.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn